TNFRSF17 and neoplasm: Higher APRIL concentrations can promote resistance to lenalidomide, bortezomib and other standard drugs, encourage the expression of programmed cell death for ligands 1 PD-L1, interleukin (IL)-10 and TGFβ on BCMA+ tumour cells as well as the creation of an immunosuppressive niche that favours tumour cells [49].